28 a 31 de Outubro de 2012
Canela, RS - Brasil
Doenças do Século XX & Estratégias de Planejamento de Fármacos do Século XXI
O 6º BrazMedChem está chegando com as novas tendências
Professor David Thurston has a first degree in pharmacy, and a PhD in synthetic medicinal chemistry through a CASE Award in the area of anti-inflammatory agents with Glaxo Ltd (now GlaxoSmithKline) supervised by Dr. Roger Newton. Subsequently, he has worked at five schools of pharmacy, two in the USA (University of Texas at Austin and Kentucky Colleges of Pharmacy), and three in the UK (Portsmouth, Nottingham and London Schools of Pharmacy). In 2000 he co-founded the oncology biotech company Spirogen Ltd for which he is presently part-time CSO. His research team discovered the first-in-class sequence-selective DNA-interactive agent SJG-136, which has recently completed Phase I clinical trials in both the US and UK. It started Phase II clinical trials in the USA in ovarian cancer earlier in 2011, and will shortly start Phase II trials in leukaemia in the UK. To date, Professor Thurston has supervised over 50 PhD students and numerous postdoctoral research fellows, and is author of over 130 publications in medicinal chemistry/chemistry journals and books. His textbook, "Chemistry and Pharmacology of Anticancer Drugs" is recognized as a standard text in the area for undergraduates, postgraduates and cancer researchers in both industry and academia, and will be moving to a second edition in 2012.